Johnson & Johnson (JNJ) Total Current Liabilities (2009 - 2026)
Johnson & Johnson (JNJ) posted Total Current Liabilities of $54.9 billion for Q2 2026, down 4.89% sequentially from $57.7 billion in Q1 2026, and up 1.32% YoY from $54.2 billion in Q2 2025.
Johnson & Johnson (JNJ) Total Current Liabilities (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Total Current Liabilities for 18 years, with the latest figure at $54.9 billion in Q2 2026.
- Quarterly Total Current Liabilities rose 1.32% year-over-year to $54.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $54.9 billion (up 1.32% YoY) and the FY2025 annual result came in at $54.1 billion, up 7.56% from the prior year.
- Total Current Liabilities retreated to $54.9 billion in Q2 2026 per JNJ's latest filing, from $57.7 billion in the prior quarter.
- Over five years, Total Current Liabilities peaked at $60.4 billion in Q2 2023 and troughed at $43.4 billion in Q2 2022.
- A 5-year average of $51.2 billion and a median of $51.8 billion in 2024 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities jumped 39.14% in 2023, then fell 19.29% in 2024.
- Over 5 years, Total Current Liabilities stood at $45.5 billion in 2022, then grew by 1.62% to $46.3 billion in 2023, then increased by 8.73% to $50.3 billion in 2024, then climbed by 7.56% to $54.1 billion in 2025, then grew by 1.42% to $54.9 billion in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $54.9 billion, $57.7 billion, and $54.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 37.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 54.90 Bn |
| Mar 29, 2026 | 57.72 Bn |
| Dec 28, 2025 | 54.13 Bn |
| Sep 28, 2025 | 50.87 Bn |
| Jun 29, 2025 | 54.18 Bn |
| Mar 30, 2025 | 56.90 Bn |
| Dec 29, 2024 | 50.32 Bn |
| Sep 29, 2024 | 51.76 Bn |
| Jun 30, 2024 | 53.93 Bn |
| Mar 31, 2024 | 48.73 Bn |
| Dec 31, 2023 | 46.28 Bn |
| Oct 1, 2023 | 44.37 Bn |
| Jul 2, 2023 | 54.17 Bn |
| Apr 2, 2023 | 60.37 Bn |
| Jan 1, 2023 | 55.80 Bn |
| Oct 2, 2022 | 45.54 Bn |
| Jul 3, 2022 | 44.82 Bn |
| Apr 3, 2022 | 43.39 Bn |
| Jan 2, 2022 | 45.23 Bn |
| Oct 3, 2021 | 44.56 Bn |